CGS 30440: A dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11

Cardiovascular Drug Reviews

Volumn 17, Issue 1, 1999, Pages 16-38

  Cohen, David S ^a   Fink, Cynthia A ^a   Trapani, Angelo J ^a   Webb, Randy L ^a   Zane, Patricia A ^a   Chatelain, Ricardo E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Angiotensin converting enzyme; Atrial natriuretic peptide (ANP); CGS 30440 CGS 30008; Mean arterial pressure; Neutral endopeptidase; Spontaneously hypertensive rat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; N [[1 (2 ACETYLTHIO 3 METHYL 1 OXOBUTYLAMINO) 1 CYCLOPENTYL]CARBONYL] O METHYLTYROSINE ETHYL ESTER;

ANTIHYPERTENSIVE THERAPY; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; HEART INFARCTION; HUMAN; HYPERTENSION; PRIORITY JOURNAL; REVIEW;

EID: 0032798398     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1999.tb00002.x     Document Type: Review

References (79)

1. Abassi Z, Haramati A, Hoffman A, Burnett JC Jr, Winaver J. Effect of converting-enzyme inhibition on renal reponse to ANF in rats with experimental heart failure. Am J Physiol 1990;259:R84-R89.
2. Anand IS, Kalra GS, Ferrari R, Wahi PL, Harris PC, Poole-Wilson PA. Enalapril as initial and sole treatment in severe chronic heart failure with sodium retention. Int J Cardiol 1990;28:341-346.
3. Anderson S, Meyer TW, Rennke HG, Brenner BM. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 1985;76:612-619.
4. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986;77:1993-2000.
5. Anderson S, Rennke HG, Brenner BM. Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 1992;41:891-897.
6. Bayliss J, Canepa-Anson R, Norell M, Poole-Wilson P, Sutton G. The renal response to neuroendocrine inhibition in chronic heart failure: double-blind comparison of captopril and prazosin. Ear Heart J 1986; 7:877-884.
7. Bevan EG, Connell JMC, Doyle J, et al. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
8. Bhagwat SS, Fink CA, Gude C, et al. α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11. Bioorg Med Chem Lett 1995;5:735-738.
9. Bohacek R, De Lombaert S, McMartin C, Priestle J, Grutter M. Three-dimensional models of ACE and NEP inhibitors and their use in the design of potent dual ACE/NEP inhibitors. J Am Chem Soc 1996;118:8231-8249.
10. Camargo MJ, von Lutterotti N, Campbell WG Jr, et al. Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade. J Hypertens 1993;11:31-40.
11. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 1988;11:239-243.
12. Chatelain RE, Ghai RD, Trapani AJ, et al. Antihypertensive and natriuretic effects of CGS 30440, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase 24.11. J Pharmacol Exp Ther 1998; 284:974-982.
13. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78:1362-1374.
14. Cohen DS, Mathis JE, Dotson RA, Graybill SR, Wosu NJ. Protective effects of CGS 30440, a combined angiotensin-converting enzyme inhibitor and neutral endopeptidase inhibitor, in a model of chronic renal failure. J Cardiovasc Pharmacol 1998;32:87-95.
15. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
16. Cushman DW, Cheung HW. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung Biochem Pharmacol 1971;20:1637-1648.
17. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981;28:89-94.
18. Deen WM, Maddox DA, Robertson CR, Brenner BM. Dynamics of glomerular ultrafiltration in the rat. VII. Response to reduced renal mass. Am J Physiol 1974;227:556-562.
19. Dworkin LD, Benstein JA, Parker M, Tolbert E, Feiner HD. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 1993;43:808-814.
20. Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991;39:1112-1117.
21. Favrat B, Burnier M, Nussberger J, et al. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. J Hypertens 1995;13:797-804.
22. Fink CA, Carlson JE, McTaggert PA, et al. Mercaptoacyl dipeptides as orally active dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1996;39:3158-3168.
23. Fink CA, Qiao Y, Berry C, Sakane Y, Ghai R, Trapani A. New α-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J Med Chem 1995;38:5023-5030.
24. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli JF. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharmacol 1993; 22:305-313.
25. Fournié-Zaluski MC, Coric P, Turcaud S, et al. New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension. J Med Chem 1994;37:1070-1083.
26. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 1981;2:543-547.
27. Gavras H, Brunner HR, Turini GA, et al. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978;298:991-995.
28. Gros C, Noel N, Souque A, et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci USA 1991;88:4210-4214.
29. Hayslett JP. Functional adaptation to reduction in renal mass. Physiol Rev 1979;59:137-164.
30. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 1981;241:F85-F93.
31. Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 1991;40:195-202.
32. Janssen WMT, de Zeeuw D, van der Hem GK, de Jong PE. Antihypertensive effect of a 5 d infusion of atrial natriuretic factor in humans. Hypertension 1989;13:640-646.
33. Kakinuma Y, Kawamura T, Bills T, Yoshioka T, Ichikawa I, Fogo A. Blood pressure-independent effect of angiotensin inhibition on vascular lesions of chronic renal failure. Kidney Int 1992;42:46-55.
34. Kenny AJ, Stephenson SL. Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide. FEBS Lett 1988;232:1-8.
35. Kohzuki M, Hodsman GP, Johnston CI. Attenuated response to atrial natriuretic peptide in rats with myocardial infarction. Am J Physiol 1989;256:H533-H538.
36. Lafferty HM, Gunning M, Silva P, Zimmerman MB, Brenner BM, Anderson S. Enkephalinase inhibition increases plasma atrial natriuretic peptide levels, glomerular filtration rate, and urinary sodium excretion in rats with reduced renal mass. Circ Res 1989;65:640-646.
37. Lee RW, Raya TE, Michael U, Foster S, Meeks T, Goldman S. Captopril and ANP: changes in renal hemodynamics, glomerular-ANP receptors and guanylate cyclase activity in rats with heart failure. J Pharmacol Exp Ther 1992;260:349-354.
38. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
39. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens 1989;11:1325-1350.
40. Margulies KB, Perrella MA, McKinley LJ, Burnett JC Jr. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. J Clin Invest 1991;88: 1636-1642.
41. Monopoli A, Ongini E, Cigola E, Olivetti G. The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20:496-504.
42. Natsume T, Kardon MB, Pegram BL, Frohlich ED. Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass. Cardiovasc Drugs Ther 1989;3:433-439.
43. O'Connell JE, Jardine AG, Davidson G, Connell JMC. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. J Hypertens 1992;10:271-277.
44. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H. Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7:943-947.
45. Olins GM, Kreiter PA, Trapani AJ, Spear KL, Bovy PR. Specific inhibitors of endopetidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo. Mol Cell Endocrinol 1989;61:201-208.
46. Orlowski M, Wilk S. Purification and specificity of a membrane bound metalloendoprotease from bovine pituitary. Biochemistry 1981;20:4942-4950.
47. Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 1987;9:178-187.
48. Pelayo JC, Quan AH, Shanley PF. Angiotensin II control of the renal microcirculation in rats with reduced renal mass. Am J Physiol 1990;258:F414-F422.
49. Pfeffer MA, Braunwald E, Moye LA, et al. The SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 1992;327:669-677.
50. Pfeffer MA, Greaves SC, Arnold MO, et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. Circulation 1997;95:2643-2651.
51. Pham I, Gonzalez W, el Amrani AI, et al. Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension. J Pharmacol Exp Ther 1993; 265:1339-1347.
52. Podjarny E, Rathaus M, Bernheim J, et al. Captopril, but not diltiazem, favorably affects the course of early chronic renal disease. Nephron 1990;55:196-202.
53. Remes J, Tikkanen I, Fyhrquist F, Pyorala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991;65:249-255.
54. Richards AM, Crozier IG, Espiner EA, et al. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure. J Cardiovasc Pharmacol 1992;20:735-741.
55. Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension 1993;22:231-236.
56. Richards AM, Crozier IG, Kosoglou T, et al. Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993;22:119-126.
57. Richards AM, Wittert GA, Crozier IG, et al. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993;11:407-416.
58. Richardson A, Bayliss J, Scriven AJ, Parameshwar J, Poole-Wilson PA, Sutton GC. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987;2:709-711.
59. Robl JA, Sun C-Q, Stevenson J, et al. Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997;40:1570-1577.
60. Seymour AA, Asaad MM, Abboa-Offei BE, Smith PL, Rogers WL, Dorso CR. In vivo pharmacology of dual neutral endopeptidase/angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1996;28: 672-678.
61. Seymour AA, Asaad MM, Lanoce VM, Langenbacher KM, Fennell SA, Rogers WL. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure. J Pharmacol Exp Ther 1993;266:872-883.
62. Seymour AA, Swerdel JN, Abboa-Offei B. Antihypertensive activity during inhibition of neutral endopeptidase and angiotensin converting enzyme. J Cardiovasc Pharmacol 1991;17:456-465.
63. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med 1991;327:685-691.
64. Stier CT Jr, Benter IF, Ahmad S, et al. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 1989;13:115-121.
65. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 1991; 4:680-687.
66. Tolins JP, Raij L. Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 1990;16:452-461.
67. Trapani AJ, Smits JFM, Sun XJ, Webb RL, Yau ET. CGS 24128: a long-acting inhibitor of neutral endopeptidase 3.4.24.11. Cardiovasc Drug Rev 1994;12:271-285.
68. Trippodo NC, Fox M, Natarajan V, Panchal BC, Dorso CR, Asaad MM. Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure. J Pharmacol Exp Ther 1993;267:108-116.
69. Trippodo NC, Panchal BC, Fox M. Repression of angiotensin II and potentiation of bradykinin contribute to the synergistic effects of dual metalloprotease inhibition in heart failure. J Pharmacol Exp Ther 1995; 272:619-627.
70. Trippodo NC, Robl JA, Asaad MM, et al. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure. J Pharmacol Exp Ther 1995;275:745-752.
71. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR. Effects of omapatrilat in low, normal and high renin experimental hypertension. Am J Hypertens 1998;11:363-372.
72. Ura N, Carretero OA, Erdos EG. Role of renal endopeptidase-24.11 in kinin metabolism in vitro and in vivo. Kidney Int 1987;32:507-514.
73. Vacher E, Forties P, Domerque V, Richer C, Bruneval P, Giudicelli JF. Quinapril prevents stroke both during and after the treatment period in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1993;6:951-959.
74. Villarreal D, Freeman RH, Johnson RA. Captopril enhances renal responsiveness to ANF in dogs with compensated high-output heart failure. Am J Physiol 1992;262:R509-R516.
75. Webb RL, Abramson ML, Beil ME, Odorico LM, Chatelain RE. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1997;30:632-642.
76. Webb RL, Barclay BW, Navarrete AE, Wosu NJ, Sahota P. Protective effects of valsartan and benazeprilat in salt-loaded stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 1998;20:775-793.
77. Wenzel UO, Troschau G, Schoeppe W, Helmchen U, Schwietzer G. Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 1992;20:233-241.
78. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramaprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991;18:558-563.
79. Zanzinger J, Zheng X, Bassenge E. Endothelium dependent vasomotor responses to endogenous agonists are potentiated following ACE inhibition by a bradykinin dependent mechanism. Cardiovasc Res 1994;28:209-214.